94 reports of this reaction
1.7% of all BENZTROPINE MESYLATE reports
#12 most reported adverse reaction
TYPE 2 DIABETES MELLITUS is the #12 most commonly reported adverse reaction for BENZTROPINE MESYLATE, manufactured by Chartwell RX, LLC.. There are 94 FDA adverse event reports linking BENZTROPINE MESYLATE to TYPE 2 DIABETES MELLITUS. This represents approximately 1.7% of all 5,542 adverse event reports for this drug.
Patients taking BENZTROPINE MESYLATE who experience type 2 diabetes mellitus should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
TYPE 2 DIABETES MELLITUS is a less commonly reported adverse event for BENZTROPINE MESYLATE, but still significant enough to appear in the safety profile.
In addition to type 2 diabetes mellitus, the following adverse reactions have been reported for BENZTROPINE MESYLATE:
The following drugs have also been linked to type 2 diabetes mellitus in FDA adverse event reports:
TYPE 2 DIABETES MELLITUS has been reported as an adverse event in 94 FDA reports for BENZTROPINE MESYLATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
TYPE 2 DIABETES MELLITUS accounts for approximately 1.7% of all adverse event reports for BENZTROPINE MESYLATE, making it a notable side effect.
If you experience type 2 diabetes mellitus while taking BENZTROPINE MESYLATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.